26th Annual Meeting of the European Charcot Foundation, 15 - 17 November 2018, Baveno (IT)
Alexey Boyko

Alexey Boyko gained his MD and PhD from the Russian State Medical University, Moscow and has been Professor of the Department of Neurology and Neurosurgery at this university since 1997. He was the Chief Neurologist of the Department of Health Care of the Government of Moscow in 2001-2015, Director of the Moscow Multiple Sclerosis Center in 2004-2014 and Director of the MS Clinical and Research Center of Neuroclinic (Ysupov Hospital) since 2015. He was elected as a Honourable Professor of Kazan and Yaroslavl State Medical Universities. Professor Boyko has been a member of the "Oslo International Think-tank on Multiple Sclerosis Epidemiology, Analytical Approaches to Study of the Aetiology" at the Center for Advanced Studies of the Norwegian Academy of Science and Letters in 1994-1995, and worked at UBC MS Center in 1998 (Vancouver, Canada). He is also a member of the Presidium of the All-Russian Society of Neurologists, Co-ordinator of the Medical Consulting Boards of Moscow and All-Russian MS Societies, President of RUCTRIMS, member of the ECTRIMS Council. Professor Boyko has published 15 books, 12chapters in books and more than 800 original publications and is a co-editor of three medical journals. The main interest is epidemiology and genetic of MS, neuroimmunology, clinical trials in MS. He is a member of several Advisory Boards of ongoing and finished clinical trials, a member of Editorial Boards of several international medical journals.

COI form

William Carroll

Dept Neurology Sir Charles Gairdner Hospital, Centre for Neuromuscular and Neurological Disorders, Perron Institute, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, Australia

Professor William Carroll is a Consultant Neurologist, Chair of the Multiple Sclerosis Research Australia International Research Review Board, President of the World Federation of Neurology, foundation Vice President of the Pan Asian Committee for Research and Treatment of MS (PACTRIMS), a member of the steering committee of the International Progressive MS Alliance (IPMSA) and Asia Pacific editor of the Multiple Sclerosis Journal. He has served previously as chair of the Multiple Sclerosis Research Australia Management Council, President of the Australian and New Zealand Association of Neurologists and President of the XV111 World Congress of Neurology 2005. His principal research activity has been in demyelinating disease, both multiple sclerosis and of the biology of demyelination and remyelination in experimental optic neuropathy.


Michel Clanet

Michel CLANET has a career as a Professor of Neurology in the University Hospital of Toulouse in the Neuroscience department that he led from 2007 to 2014. His field of expertise relates to inflammatory demyelinating diseases of the nervous system, especially multiple sclerosis (MS). His research activity was mainly devoted to MS genetic susceptibility and therapeutic research. He is currently a member of the Executive Committee of the French MS Observatory (OFSEP). He has always been working to promote research on these diseases, at the national level as Chair of the Scientific Committee of the ARSEP Foundation (1990-2000) and at the international level as President of the European Committee for Treatment and Research in MS (ECTRIMS) (2010-2012). He also participated in the creation of the Federation for Brain Research, of which he was chairman of the scientific council following Professor Jacques Glowinski. He has also been deeply involved in the teaching and promotion of neurology in the different neurological institutions during his tenure as president (College of Neurology Teachers, French Society of Neurology, neurology sub-section of the National Council of Universities). Improving the care and support of persons with neurological disabilities has been his constant concern in innovative programs such as the creation of a regional resources pool to support persons with neuro-degenerative diseases.

He is currently chair of the executive committee of National Neuro-Degenerative Diseases Plan 2014-2019 launched by the Ministry of Solidarities and Health and vice-chair of the “Commission de Transparence” of the National Health Authority (HAS).

COI form


Giancarlo Comi

Giancarlo Comi is Professor of Neurology, Chairman of the Department of Neurology, and Director of the Institute of Experimental Neurology at Vita-Salute San Raffaele University, Milan, Italy. He is also President of the European Charcot Foundation (ECF), a member of the Board of Administration of the Italian Multiple Sclerosis Foundation and of the Scientific Committee of Associazione Italiana Sclerosi Multipla, Co-Chair of the Scientific Steering Committee of the Progressive MS Alliance, and a fellow of the European Academy of Neurology (EAN). He has served as a past president of the European Neurology Society, the Italian Society of Clinical Neurophysiology, and the Italian Society of Neurology.

In recent years, Professor Comi has received the ‘Gh. Marinescu’ honorary award from the Romanian Society of Neurology, and has been awarded honorary memberships of the Russian Neurological Academic Society, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the European Neurological Society (ENS) and the Sociedad Espanola de Neurologia. He also received the Charcot Award for MS Research from the MS International Federation (MSIF) in 2015. In the past year Professor Comi was awarded the Gold Medal of ‘Benemeranza Civica’ from the City of Milan and has been recently conferred the honor of merit as Official by the President of Italy.

Prof. Comi has authored and co-authored more than 1000 articles in peer-reviewed journals, and edited several books, with an h-index of 100. He has been the invited speaker for more than 450 conferences, both nationally and internationally. He sits on the executive boards of various scientific associations and on the editorial boards of Clinical Investigation, European Journal of Neurology and Multiple Sclerosis. He is also the Associate Editor of the Neurological Sciences.

COI form

Bruce A. Cree

Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology in the Department of Neurology at the University of California San Francisco.Dr. Cree completed his MD and PhD in Biochemistry at UCSF.His neurology residency training was at Columbia University.He returned to UCSF for a Sylvia Lawry National Multiple Sclerosis Society fellowship and received a Masters in Advanced Studies in Clinical Research.He is the Clinical Research Director at the UCSF MS Center and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis. He divides his time between patient care, clinical research and teaching.His research focuses on the genetic epidemiology of multiple sclerosis, understanding factors that contribute to disease progression and developing novel therapies for MS through clinical trials.In addition to multiple sclerosis, Dr. Cree specializes in research and care of patients with neuromyelitis optica and transverse myelitis.

COI form

Gloria Dalla Costa

Dr. Gloria Dalla Costa, MD received her medical degree from San Raffaele University and completed her residency in neurology there. She has extensive training in treating Multiple Sclerosis Patients and has followed several clinical trials according to Good Clinical Practice. She is part of the Clinical Research Unit on CNS Disorders (PI Dr. V. Martinelli) and collaborates with the Clinical Neuroimmunology Research Unit (PI Dr. R. Furlan). Her main focus of research is on environmental risk factors of MS and biomarkers and prognostic factors in patients with clinically isolated syndromes, among which she is focusing on NfL.

COI form

Gilles Edan

Gilles Edan is currently professor of clinical neurology and chair of the Department of Neurosciences at the University Hospital of Rennes, France. After completing his MD at the University of Rennes in 1981, he went on to specialize in neurology under the supervision of Pr Olivier Sabouraud , was a research fellow at Guy’s hospital (London) in neuroimmunology with RAC Hughes in 1987, spent a sabbatical period of 6 months at the MS clinic of UBC with Don Paty and Joel Oger in Vancouver in 1996 and set up a MS clinic in Brittany in 1996. Gilles Edan was one of the members of the international panel for the new diagnostic criteria of MS (Mc Donald criteria) in 2001 and 2005. He published more than 200 peer-reviewed original papers on his MS researches in Journals and several chapters in books on these subjects.

COI form

Franz Fazekas

Franz Fazekas is Professor of Neurology, head of the Department of Neurology and director of the Division of General Neurology at the Medical University of Graz, Graz, Austria.

Dr. Fazekas obtained his medical degree from Karl–Franzens University in Graz, where he also received his training in neurology and psychiatry. After a 2-year fellowship at the University of Pennsylvania, Philadelphia, USA Dr. Fazekas has focused his research on the diagnosis and treatment of multiple sclerosis and cerebrovascular diseases in combination with neuroimaging tools, especially magnetic resonance imaging (MRI).

Professor Fazekas has been President of the Austrian Society of Neurology and the Austrian Society for Stroke Research. He is also a past member of the Executive Committee of ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and of MAGNIMS (Magnetic Resonance in MS). Currently, he is a Vice President of the European Charcot Foundation and President of the European Academy of Neurology (EAN). Professor Fazekas has authored more than 500 peer-reviewed papers and several book chapters, and serves on various scientific Advisory, Editorial and Review Boards.

COI form

Anthony Feinstein

Dr. Feinstein received his medical degree in South Africa at the University of the Witwatersrand.Thereafter he completed his training in Psychiatry at the Royal Free Hospital in London, England, before training as a neuropsychiatrist at the Institute of Neurology, Queen Square in London. His Master of Philosophy and Ph.D. Degree were obtained through the University of London, England.He is professor of Psychiatry at the University of Toronto.

His research focuses on the search for cerebral correlates of behavioral disorders associated with multiple sclerosis, traumatic brain injury, and hysteria (Conversion Disorders). He is past Chair of the Medical Advisory Committee of the Multiple Sclerosis Society of Canada.

Dr. Feinstein is the author of In Conflict (New Namibia Books, 1998), Dangerous Lives: War and the Men and Women Who Report It (Thomas Allen, Toronto 2003), The Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press 1999, with a second edition in 2007), Michael Rabin, America’s Virtuoso Violinist (Amadeus Press, 2005, second edition, 2011; audiobook, 2017), Journalists Under Fire: the Psychological Hazards of Covering War (John Hopkins University Press, 2006) and Battle Scarred (Tafelberg Press, 2011). His new book Shooting War (Glitterati Editions) is due out in late 2018. He has published widely in peer-reviewed journals and has authored many book chapters.

In 2000-2001 he was awarded a Guggenheim Fellowship to study mental health issues in post-apartheid Namibia. In 2012, he produced a documentary, “Under Fire” based on his research of journalists in war zones. It was shortlisted for an Academy Award and won a 2012 Peabody Award. His series Shooting War (http://tgam.ca/ShootingWar) for the Globe and Mail Newspaper was shortlisted for a 2016 EPPY award.

COI form

Oscar Fernandez

Oscar Fernandez, is Senior Investigator at Instituto de Investigacion Biomedica de Malaga (IBIMA) and
Hospital Regional Universitario in Malaga, Spain. He is Honorary Professor at the Faculty of Medicine of the
University of Malaga. He received his medical degree from Complutense University in Madrid and the PhD
degree from Malaga University. Dr Fernandez earned his ECFMG (External Council for Foreign Medical
Graduates) certificate of the USA, and specialist certificate in neurology and internal medicine from San
Carlos University Hospital in Madrid. Has been the founder and first Director of the Service of Neurology
and thereafter of the Institute of Clinical Neurosciences at Hospital Regional Universitario de Malaga. His
research background includes more than 200 peer- reviewed published papers, 67 book chapters, and
participated in 120 clinical trials (acting as principal investigator for numerous phase II and III trials). Dr.
Fernandez is Founder and Editor of the journal, Revista Española de Esclerosis Multiple. He is a member
of several national and international neurological organizations including having had the position of President
of the Spanish Society of Neurology.

COI form


Mark Freedman

Mark Freedman is Professor of Medicine (Neurology) at the University of Ottawa, Senior Scientist at the Ottawa Hospital Research Institute and Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital-General Campus.

His extensive research includes molecular neurochemistry, cellular immunology, and clinical studies in MS. His basic science interest concerns immune mechanisms of damage in MS, with a particular interest in the role of the innate immune system such as gamma-delta T-cells. His main clinical interests are cell-based therapies for MS. He was the lead investigator of the Canadian Bone Marrow Transplant Study in MS and he co-heads an international study of mesenchymal stem cells for the treatment of MS. He is the current Treasurer of ACTRIMS.

COI form

Kazuo Fujihara

Kazuo Fujihara, M.D. is Professor, Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Director, Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama 963-8563, Japan. Dr. Fujihara is a neurologist and has mainly worked in the field of multiple sclerosis (MS), neuromyelitis optica (NMO) and related neuroimmunological disorders. He contributed to the 2010 and 2016-2017 Revisions to McDonald Criteria in the International Panel on Diagnosis of MS, and is a member of the International Panel on NMO Diagnosis. He has also served on the Board of European Charcot Foundation (2013~), the Executive Committee, International Medical and Scientific Board of The Multiple Sclerosis International Federation (2013~) and an External Reviewer of Malaysian Clinical Practice Guidelines (CPG), Management of Multiple Sclerosis. He is an inaugural member and Deputy Secretary of PACTRIMS and a co-convener of “MS and Other Inflammatory Diseases” in the 23rd World Congress of Neurology (2017, Kyoto). He is a member of International Advisory Board of Sri Lankan Journal of Neurology (2012~), an Honorary Corresponding Member of the Indian Academy of Neurology (2015~), and an Honorary Fellow of the Hong Kong Multiple Sclerosis Society (2015~).

COI form

Angelo Ghezzi

Dr Angelo Ghezzi is chief emeritus of Neurology. He is the responsible of scientific research at Multiple Sclerosis Study Centre of St Antonio Abate Hospital in Gallarate, Italy, the oldest Italian MS center. He is member of the Steering Committee of the International Pediatric MS Study Group, and member of the Italian MS Study Group of the Italian Neurological Society Dr Ghezzi has been an active researcher, serving as an investigator in many international Phase II and III trials. His research has focused on the areas of optic neuritis, MS and pregnancy, MS and sexual disturbances, MS and epilepsy, MS evolution and prognosis, MRI and clinical correlation with MS, and clinical neurophysiology (evoked potentials, pelvic floor neurophysiology); however, he is especially interested in the clinical and therapeutic aspects of pediatric MS (MS onset in childhood-adolescence, immunomodulatory treatment of juvenile-onset MS). Dr Ghezzi is the editor of 10 books on multiple sclerosis, and author or co-author of more than 200 articles published in international journals.

COI form

Hans-Peter Hartung

Professor Hartung received his undergraduate training at the Universities of Düsseldorf, Glasgow, Oxford and London. After graduation magna cum laude as MD in 1980 he served an immunology fellowship at JohannesGutenberg-University of Mainz. He started his career in neurology at the University of Düsseldorf, where he became assistant professor in 1987. He was appointed professor and head of the MS clinical research group and Vice Chair of the Department of Neurology at Julius-Maximilians-University of Würzburg in 1990 and moved in 1997 to Graz, Austria, to become chairman of the University Department of Neurology. He is currently chair of the Department of Neurology at Heinrich Heine University Düsseldorf, a position he has held since 2001, and since 2012 director of the Center for Neurology and Neuropsychiatry. He is also Medical Director of the Department of Conservative Medicine at Düsseldorf University Hospital.

Professor Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has authored or co-authored more than 900 articles in peer-reviewed journals, one hundred book chapters and edited nine books. He is a Highly Cited Researcher 2017 (Web of Science).

He was President of ECTRIMS and has served / serves amongst others on the executive boards of the European Charcot Foundation, the International Society of Neuroimmunology, Peripheral Nerve Society, INC,WHO Working Group on Multiple Sclerosis, GBS CIDP Foundation International, MSIF and the German MS Society and theUS NMS Society and ECTRIMS clinical trials committee. He is member of the executive board of IMSCOGS. He is/ was also member of the Editorial Board of a number of international journals.

COI form

Jan Hillert

Dr Hillert is a professor of neurology at Karolinska Institutet in Stockholm Sweden and consultant in neurology at the Karolinska Univeristy Hospital since 2001 where he also holds the position as Director of research and Education. Dr Hillert’s special interest, both clinically and in research, is multiple sclerosis (MS). In 1995 he started what in 2000 became the national Swedish Multiple Sclerosis Registry, SMSreg, one of the leading MS regsitries witt currently over 80 % of prevalent MS patients in Sweden assessed, at an average for over 7 years. Starting in the late 1980:ies Dr Hillert focused on the genetics of MS and contributed to what eventually became a success story with over 200 MS loci discovered through the joint efforts of the International MS Genetics Consortium. In recent years, his research efforts have moved into other aspects of MS epidemiology including pharmacoepidemiology and health economics and outcomes research, in MS. An important aim for Dr Hillert is the development of registries within MS and neurology in general and international collaboration between such registries and data bases, such as in the Big MS Data initiative. Dr Hillert has published over 260 original papers.

COI form


Pietro Iaffaldano

Pietro Iaffaldano is currently an Assistant Professor of Neurology at the University of Bari, Italy (from 04/01/2016). Pietro has more than 10 years of experience working both as clinician and researcher. Since 2005 he attended, at first as student then as resident, the Multiple Sclerosis research group of the University of Bari directed by Prof Maria Trojano. He took part actively in the management of Multiple Sclerosis patients using standardized protocols for diagnosis and treatment. From 2013 to 2015 he was a scientific consultant of the Mario Negri Sud foundation, working closely to the IT research group involved in the technical and statistical management of the iMedWeb project. Main research interests are epidemiology and in particular pharmaco-epidemiology, data-management of big data sets, cognition and cognitive rehabilitation techniques applied to multiple sclerosis. The main research skills are: data management of big data sets using different IT tools. He has published 40 original contributions in the MS field on international peer-reviewed journals.

COI form

Ludwig Kappos

Grown up in Athens, Greece Ludwig Kappos obtained his M.D. and a Diploma in Clinical Psychology from the University of Würzburg, Germany, in 1980, where he went on to specialise in Neurology and Neuroimmunology, and became Deputy Chief, Division of Clinical Neurology, Max Planck Society, Clinical Research Unit for Multiple Sclerosis. In 1990 he was elected Head of the Outpatient Department, Neurology/Neurosurgery and since 2008 Chair of Neurology at the University of Basel, Switzerland. Research interests include immuno-logical and molecular studies in neuroimmunological diseases, methodology and conduct of therapeutic studies mainly in the field of MS, standardisation of clinical assessment, development of biomarkers and use of magnetic resonance tomography in elucidating the pathogenesis of inflammatory CNS disease and as tool in monitoring therapeutic studies. Ludwig Kappos serves as chair or member in several steering committees and advisory boards of Clinical Trials and Organizations active in the field of MS and general Neurology. Ludwig Kappos has published more than 670 original papers, reviews and book chapters. He has been awarded with several prizes and honorary doctorates for his scientific contributions.

COI form

Sami L. Khella

Sami Khella is Professor of Clinical Neurology at the University of Pennsylvania School of Medicine.He has done research in the treatment of immune mediated neurological disorders like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy (CIDP) for many.He has published widely on these topics.More recently, he helped establish the University of Pennsylvania Amyloid Center, which is one of the largest centers in the United States of America.His experience with amyloid neuropathy is extensive.

Dr. Khella founded a popular nationally renowned course on immunotherapy for neurologic disorders.He has won many teaching awards including most recently the Blockley-Osler award for excellence in teaching neurology students and residents.

In his other life, when he’s not playing football (soccer), is as a painter and printmaker, where many of his paintings hang in important private and public collections.

COI form

Eva Kubala Havrdová

Dr Eva Kubala Havrdova is Professor of Neurology at the First Faculty of Medicine, General University Hospital, Charles University in Prague, Czech Republic.

She obtained her medical degree at the same university in 1981 and went on to specialize in neurology and became Professor at Charles University in 2010. She is currently Director of the Center for Demyelinating Diseases at Charles University, Prague.

Dr Kubala Havrdová’s research interests include cytokine, immunoglobulin & T-cell research in multiple sclerosis, treatment of malignant MS. She created “freedom from disease activity” concept used now to compare efficacy of MS drugs. She has published more than 100 publications on multiple sclerosis including Neuroimmunology, Multiple Sclerosis, Handbook on MS for General Practitioners, Pharmacotherapy of MS, and several books for patients.

She organized ECTRIMS Congress in Prague in 2007, is a member of MSIF International Medical and Scientific Board, and member of the Czech Neurological Society Committee. She introduced disease modifying treatment in MS in Czech Republic and established a network of MS Centers covering all the country. She developed Standards of Diagnostics and Treatment of MS and NMO in Czech Republic.

COI form

Dawn Langdon

Dawn Langdon completed her training as a clinical psychologist at Oxford University and the Institute of Psychiatry, KCL. She worked as a clinical neuropsychologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London for sixteen years, obtaining a PhD on reasoning in organic brain syndromes from the Institute of Neurology, UCL and registration as both a neuropsychologist and a health psychologist.

She is now Professor of Neuropsychology and Director of Health and Medicine at Royal Holloway, University of London. She is also a Fellow of the British Psychological Society. She is neuropsychology lead on a number of multinational trials for the pharmaceutical industry. She has worked extensively on psychological aspects of MS, including measurement of cognition and it’s relation to pathology and other disease variables. She is also investigating how risks and benefits of MS medication are best communicated to patients, including a successful randomised control trial comparing the new protocol to consultation as usual. Other interests are how employment relates to cognition in MS and the measurement of cerebellar function.

She is Co-Chair of the BICAMS initiative (www.BICAMS.net), which has recommended a brief cognition tool for MS. There are currently 36 countries in the national validation pipeline, of whom 15 have published. The AAN have recommended BICAMS as part of its Quality Measurement Set for MS. Over 30 peer review journals recommend BICAMS for routine assessment. BICAMS has been used in a number of international pharma trials and some high profile investigations of MS cognition relating to imaging, employment and everyday life tasks. Dawn Langdon has led on the development of IPAD BICAMS.

She is a frequent contributor to international scientific meetings and committees and is a Trustee of the UK MS Trust, with whom she has authored the MS cognition website www.stayingsmart.org.uk. She is Co-Chair of MS in the 21st Century (https://www.msinthe21stcentury.com).

Michael Lawton

I have been studying, researching and working in the areas of medical statistics and statistics for more than 15 years.Some of my previous experience was in the pharmaceutical industry and covered statistics, data management and pharmacovigilance. I have been working in the department of Population Health Sciences (nee.Social and Community Medicine) at the University of Bristol as a medical statistician for the last seven years. Also, I have been teaching on statistical short courses and epidemiology to Medical Students since 2014. My first project in 2011 was concerning prognosis in patients with Multiple Sclerosis, building a model for the natural untreated history of MS patients to apply to the UK Risk Sharing Scheme.Since 2013 I have been working on a project looking at two large incidence cohorts of patients with Parkinson’s disease and for the last year I have been line-manager for someone working on the same project.As well as carrying out statistical analyses I am involved in both cohorts as a data manager, so I work to ensure data quality and have recently created a database in REDCap for one of these cohorts.At present I am carrying out a Phd based on my published work looking at prognosis in Multiple Sclerosis and Parkinson’s disease. My current interests are in prognostic models that adjust for missing data, looking at non-linearity and taking into account clustering.

Outside of work I like to play tennis, cycle and when the weather is right skiing.I love to cook and travelling to exotic places mainly for photography and to sample the local cuisine.

COI form

Letizia Leocani

Letizia Leocani is Associate Professor of Neurology at San Raffaele University and Supervisor of the Experimental Neurophysiology Unit and of Magnetic IntraCerebral Stimulation center. She had a PhD in Human Physiology and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in Bethesda-USA. Her fields of interest involve translational validation of electrophysiological and OCT markers of neurological diseases and of treatment using non invasive brain stimulation.

COI form

Johannes Lorscheider

Dr Johannes Lorscheider graduated in medicine and received an MD from the Albert-Ludwigs University of Freiburg, Germany in 2009.

He went on to specialize in neurology at the University Hospital Basel, Switzerland. In 2015, he performed a one-year clinical and research fellowship in MS at the Royal Melbourne Hospital, Australia, working with the MSBase study group. After his return to Basel, he completed his board certification in neurology in 2017.

He currently works as a consultant neurologist at the University Hospital Basel with a special interest in MS. His main research focus is observational cohort studies and clinical outcomes research in MS.

COI form

Melinda Magyari

Melinda Magyari, MD, PhD is a consultant neurologist at The Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen and the director of The Danish Multiple Sclerosis Registry.

Her clinical interests are multiple sclerosis and other inflammatory disorders of the central nervous system.

Melinda Magyari’s major research area is in multiple sclerosis epidemiology, with a particular interest in gender differences in multiple sclerosis.

During the past years, Melinda Magyari has been involved in several registry studies addressing questions regarding reproductive issues and risk factors in multiple sclerosis. Her current research is focused on observational studies investigating the efficacy, safety and social consequences of MS therapies using real world data from registries. Furthermore, she is engaged in a multi-center treatment trial investigating new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.

She is strongly involved in international collaborations with other multiple sclerosis databases and is a member of the BIG MS steering committee

She has authored more than 50 articles indexed on PubMed. She is secretary of The Danish Multiple Sclerosis Group network and the leader of the quality database The Danish Treatment Registry.

COI form

Ariel Miller

Ariel Miller, M.D., Ph.D.Prof.Ariel Miller holds a M.D. degree from the “Sackler” school of Medicine, Tel-Aviv, and a Ph.D. degree in Experimental Sciences (Neurobiology) from the Hebrew University of Jerusalem. He is a senior neurologist since 1989. From 1989 to 1992 he was a research fellow at the Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, as a scholar of the Fogarty International Research Fellowship (N.I.H.).He is currently the headof The Center for Multiple Sclerosis & Neuroimmunology Unit,at Carmel Medical Center, associated with The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.Prof. Miller is elected member of the American Neurological Association (ANA)(2005), and the recipient of the Hershel Rich Technion Innovation Award –2006,for his contribution in the field of Pharmacogenetics and 'Personalized Medicine'. He is the Founder of the Israel Society of Neuroimmunology.Prof. Miller's scientific and medical work is dedicated to elucidation of the mechanisms underlying Braindiseases,with special focus on implementation of therapeutic strategies for Multiple Sclerosisas well as Pharmacogeneticstowards development of 'Personalized Medicine'.

COI form


Xavier Montalban

Dr. Montalban is the Director of the Division of Neurology at the University of Toronto and Director of the MS centre at St Michael’s Hospital in Toronto. Also, he currently Chairs the Department of Neurology-Neuroimmunology and is the director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona. He is the former director of the Department of Neuroscience and Chief of the Neuroimmunology Research Group at the Vall d’Hebron Research Institute. Dr. Montalban received his medical license, trained as a Neurology specialist and completed his PhD in neuroimmunology during the 1980s at the Universitat Autònoma de Barcelona. He went on to undertake a postdoctoral fellowship at the Lupus Research Institute, Guy’s & St. Thomas’ Hospital plus additional clinical training at the National Hospital for Neurology and Neurosurgery, Queen Square in London, United Kingdom.

Dr. Montalban is Vice-President of Fundació Esclerosi Múltiple (MS Foundation), President of the Fundació Cemcat and former President of the Executive Committee of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). He is a member of the US National Multiple Sclerosis Society Clinical Trials Committee and he chairs the Medical & Scientific Board of the Multiple Sclerosis International Federation (MSIF). He is a member of the Board of the European Charcot Foundation.

In the past twenty years, Dr. Montalban has been in the inception phases and on steering committees of many clinical trials related to multiple sclerosis. He has authored over 600 original and revision publications in international peer-reviewed journals, as well as several book chapters. Recently, he co-directed the development of the first ECTRIMS-EAN Multiple Sclerosis Treatment Guidelines. He is the editor of the Clinical Cases Section of the Multiple Sclerosis Journal.

His research interests include clinical trials, clinical aspects of MS, MR imaging and biological prognostic factors of disease evolution and treatment response, immunological mechanisms of the disease and other aspects of clinical management of MS.

COI form

Jacqueline Palace

Dr Jackie Palace is a consultant neurologist in Oxford and Associate Professor of Nuffield Department of Clinical Neurosciences, Oxford University. She leads the Oxford Multiple Sclerosis group and runs a national service for congenital myasthenic syndromes (CMS) and jointly a UK neuromyelitis optica service (NMO) which includes adults and children. Her MS service comprises a regional clinical service and a clinical research group. Her research interests covers MS, NMO, CMS and myasthenia gravis and include clinical treatment trials, immunological studies, pathology, biomarkers, genetics and imaging studies on neurodegeneration and its detection and association with inflammation. She has been a UK lead for the National Risk Sharing Scheme which assessed the long-term effectiveness for disease modifying agents in multiple sclerosis, is a board member for the European Charcot Foundation, on the steering committee for MAGNIMS and is the Oxford lead for the European Rare Network for Neuromuscular diseases. She is an elected member of council for the Association of British Neurologists.

COI form

Liesbet Peeters

Liesbet M. Peeters is a postdoctoral researcher at the Biomedical Research Institute of Hasselt University (Belgium). In 2013, she finished her PhD in Bio-Engineering Sciences at the KULeuven in Belgium. She has expertise in molecular genetic- and immunological techniques as well as quantitative genetic analysis. Liesbet is familiar with statistical programs, several data management software and has experience in Bio-informatics. Her research focusses on developing data sharing procedures using the FAIR principles (=Findable, Accessible, Interoperable and Re-usable). Liesbet has been invited to speak at several international conferences to summarize her data sharing vision. She attended the European Medicine Agency (EMA) patient Registry Initiative workshop on Multiple Sclerosis and participated at the stakeholder meeting of the Horizon2020 project MultipleMS in 2017. She is a member of the advisory board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) initiative “European Health Data Platform”. She has recently been appointed as the lead investigator of the BeNeLuxAI MS project investigating challenges around joint drug assessment and data exchange. She is one of the main initiators of the MS Data Alliance. The MS Data Alliance aims to increase data quality by increasing the awareness of the importance of real world data and to decrease the effort to find, access and re-use data through the development of tools for data discovery and sharing. The MS Data Alliance implements a true federated philosophy ensuring the autonomy and independence of the stakeholders involved. The MS Data Alliance brings together registry holders, patients, medical societies, academia, industry, MS umbrella organisations, The EMA and Health Technology Assessment (HTA) bodies. She is a member of the ELIXIR community focussing on constructing a sustainable infrastructure for the sharing of biological information throughout Europe. Elixir includes 20 countries covering more than 180 research organisations all over Europe. Also, ELIXIR collaborates closely with other key European and global initiatives and many of the existing ESFRI Research Infrastructures and e-infrastructures.

COI form

Juan Ignacio Rojas

Dr. Juan Ignacio Rojas is a Neurologist of the Multiple Sclerosis Department at the Italian Hospital of Buenos Aires, Argentina. Dr. Rojas studied for his Masters in Clinical and Sanitary Effectiveness at the Harvard School of Public Health in Buenos Aires between 2005 and 2010. In 2012, Dr. Rojas completed his Masters in Health Economics and Pharmacoeconomics at Pompeu Fabra University. He also has a Masters in Neuroimmunology, for which he studied at the University of Barcelona. Between 2007 and 2010, Dr. Rojas completed fellowships in Neurology and Neuroimmunology and Demyelinating disease at the Italian Hospital of Buenos Aires, Argentina.

COI form

Sven Schippling

Prof. Sven Schippling is currently Deputy Head of the Department of Neuroimmunology and Clinical Multiple Sclerosis Research (nims) at the University Hospital Zurich, Switzerland. He is the Co-Director of the Clinical Research Priority Program MS (CRPPMS) and Consultant Neurologist at the Department of Neurology at the University Hospital Zurich. He is a Senior Group Leader at the Neuroscience Center Zurich of the Federal Institute of Technology Zurich (ETHZ) and the University of Zurich (UZH). Prior to this, he was Head of the first MS Day Clinic in Germany at the University Medical Center of Hamburg University, Germany. From 2005 to 2006 he was a Postdoctoral Research Fellow at the Institute of Neurology, University College London, UK and the National Hospital for Neurology and Neurosurgery, London.

Prof. Schippling’s areas of special interest are clinical neuroimmunology, mainly within the fields of multiple sclerosis (MS) and neuromyelitis optica spectrum disease (NMOSD). His research focuses include multimodal imaging methods in MS, such as magnetic resonance imaging and optical coherence tomography, transcranial magnetic stimulation and clinical trials including stem cell therapies in MS.

Prof. Schippling is also a member of the steering group for the ‘MS in the 21st Century’ initiative, the multinational OCTIMS, BENEFIT11, EMPIRE, ENSEMBLE and CLARIFY-MS trials and has authored numerous peer-reviewed publications.

COI form

Krzysztof Selmaj

Dr. Selmaj is the Professor of Neurology at the Medical University of Lodz (MUL) and a Visiting Associate Professor at Albert Einstein College of Medicine, New York. He is a Chairman at the Department of Neurology and Director of the Neuroimmunology Laboratory at the MUL. Dr. Selmaj received training in neurology and neuroimmunology at the Charing Cross and Westminster Medical School, University of London, and at Albert Einstein College of Medicine, New York. Dr. Selmaj has been elected to serve as a Vice-President of the European Federation of Neurological Societies (EFNS) in 1999-2005 and a member of several other international advisory boards. He wasa President of the Polish Neurological Society. He served as a member of the editorial boards for European Journal of Neurology,Journal of Neuroimmunology, and Polish Neurology and Neurosurgery.His research activity considers investigations in neurobiology and neuroimmunology with a particular interest in mechanisms of demyelination and multiple sclerosis. He published over 150 papers in the field of neurology and immunology.

Alessio Signori

Alessio Signori is currently Researcher in Medical Statistics at University of Genoa, Italy. He works in Multiple Sclerosis (MS) field since 8 years. During the PhD in Biostatistics, obtained in 2013 and, subsequently, as post-doc in Biostatistics, under the supervision of Prof. Maria Pia Sormani, he was involved mainly on methodological aspects of projects on MS patients. In 2011 he was visiting fellow at Neurological Centre of McGill University in Montreal under the supervision of Prof. Douglas Arnold. In 2015 he was recipient of the MSBase Fellowship. He had 3 oral presentation at ECTRIMS (2012,2016) and EAN (2014). At August 2018 he is author or coauthor of more than 120 publications on International Journals.

COI form

Per Soelberg Sorensen

Per Soelberg Sorensen is Professor of Neurology at the University of Copenhagen and senior consultant at Department of Neurology, Rigshospitalet, Copenhagen. He is the founder of the Danish Multiple Sclerosis Center. Core elements in his research include development of new MS therapies, translational and biomarker research, and he has initiated and conducted several large international trials. He has authored more than 400 scientific publications, 353 of which are indexed in PubMed. Professor Sorensen was Founding Editor‐in‐chief of the European Journal of Neurology from 1994 to 2003 and is currently member of the editorial board of Multiple Sclerosis Journal, European Journal of Neurology, Therapeutic Advances in Neurological Disorders, and Multiple Sclerosis and Demyelinating Disorders.
Professor Sorensen is Secretary General of the European Committee for Treatment and Research in Multiple sclerosis (ECTRIMS); Executive Board member of the European Academy of Neurology; Executive Board member of the European Charcot Foundation for Research in Multiple Sclerosis; Member of the Medical Advisory Board of the International Federation of Multiple Sclerosis Societies (IFMSS); Member of the International Advisory Committee on Clinical Trials in MS, under the sponsorship of the US National MS Society and ECTRIMS; and Chairman of the Danish Multiple Sclerosis Group.

COI form

Maria Pia Sormani

Dr Maria Pia Sormani is Professor of Biostatistics at the University of Genoa, Italy. She received her Master in Biostatistics at the University of Milan, her Master in Biophysics at the University of Pisa and her degrees in Physics at the University of Genoa, in Italy. She collaborated for more than ten years with the Neuroimaging Research Unit at the S.Raffaele Hospital in Milan, studying the methodological issues related to the use of Magnetic Resonance Imaging in Multiple Sclerosis. She worked for about twelve years at the National Institute for Cancer Research in Genoa in cancer clinical studies. She serves on the National MS Society Clinical Trials Advisory Committee. She is on the faculty at the University of Genoa, where she teaches Biostatistics and Research Methods to students in medicine. She is Visiting Professor at the Imperial College of London. She is in the editorial Board of Multiple Sclerosis Journal. She published more than 340 papers on peer reviewed journals.

COI form

Maria Trojano

Maria Trojano is Professor of Neurology at the University of Bari, Italy andis currently Head of the Department ofBasic Medical Sciences, Neurosciences and Sense Organs and Director ofthe Neurology and Neurophysiopathology Units at the same University.

Professor Trojano was President (2012-2014) of the European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS). She is Honorary Member of ECTRIMS. She is currently Member of the International Advisory Committee on Clinical Trials in MS, under the sponsorship of the US National MS Society and ECTRIMS.Since 2000 she is Chair of the Italian Multiple Sclerosis Registry. She is involved in a number of Advisory Committees on clinical trials of new agents in MS.She was member of the Education committee of theEuropean Academy of Neurology (EAN) and of Medical and Scientific Advisory Board of Multiple Sclerosis International Federation (MSIF).
She is active in the design, implementation and analysis of phase IV clinical trials in MS and conducts basic and applied research in Neuroepidemiology and Neurochemistry/Neuroimmunology. She has published over 300 original contributions in the MS field on international journals and has authored a large number of book chapters.

Charidimos Tsagkas

Dr. Charidimos Tsagkas grew up in Athens and graduated in medicine and obrained his M.D. at the Kapodistrian University of Athens, Greece in 2014. He went on to specialize in neurology at the University Hospital Basel, Switzerland and begun his PhD studies focussing spinal cord atrophy in multiple sclerosis. In 2018 he obtained his Dr. med. and he is expected to finish his PhD studies before the end of 2018. He currently works as a resident neurologist at the University Hospital Basel with a special interest in multiple sclerosis and as researcher in the Translational Imaging in Neurology (ThINk) Basel Group. His main research focus remains neuroimaging studies in MS.

COI form

Bernard Uitdehaag

Prof. dr. Bernard M.J. Uitdehaag (1958) studied medicine in Nijmegen and was trained in neurology in Amsterdam. In Amsterdam he was also trained in epidemiology. He is involved in MS research since 1985 end did his PhD in MS research in 1998. In 2009 he became a professor of neuro-epidemiology and in 2010 chair of the department of Epidemiology and Biostatistics in the VU University Medical Center in Amsterdam. In 2013 he became professor of Neurology and chair of the Department of Neurology in the VU University Medical Center in Amsterdam. In 2013 he also became Director of the VUmc MS Center Amsterdam. Between 2006 and 2014 he was member of the Netherlands Society of Neurology, being president from 2011 until 2014. He (co-)authored around 300 scientific papers.

COI form

Patrick Vermersch

Patrick Vermersch studied medicine at the University Hospital in Lille, where he graduated in neurology. He then completed his education in more basic research fields, mainly in cellular biology between 1990 and 1994 with a PhD focused on biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He has also conducted research related to the characterisations of post-transcriptional anomalies of Tau proteins. His research interests then turned to multiple sclerosis (MS). Prof. Vermersch is head of one of the departments of neurology at the University of Lille, which deals with MS and other neuroinflammatory diseases. The department’s principal scientic interests are neuroimmunology and markers of disease evolution. Prof. Vermersch is currently vice-president of the University of Lille, with the responsabilities of research in life sciences and health. In the year 2000, he created with colleagues the first MS network in northern France to improve both care and research into MS. His current areas of interest are prognostic markers of MS and neuroimmunology in general. He participates in many therapeutic protocols on MS. He has published approximately 380 scientific papers as author or co-author.

Sandra Vukusic

Sandra Vukusic is professor of Neurology and head of the Multiple Sclerosis clinic (Neurology dept. A) at the Lyon University Hospital, France. She is President of the EDMUS Foundation, scientific coordinator of the Observatoire Français de la Sclérose en Plaques(French MS registry) and member of the Lyon Neuroscience research center (CRNL, UMR CNRS 5292 & Inserm U1028).

Besides her neurological training in Lyon, France, she also has a PhD in neuro-epidemiology. Together with her mentor Christian Confavreux, she has been working since 1998 on the description of the natural history of multiple sclerosis through the Lyon multiple sclerosis (MS) Cohort, introducing new pathophysiological concepts. She continues to develop epidemiological projects on long-term effect of immunoactive drugs on disability progression, pregnancy issues and pharmacoepidemiology of disease-modifying drugs.

COI form